Abstract A systematic review was conducted to identify evidence-based interventions (EBIs) for increasing HIV medication adherence behavior or decreasing HIV viral load among persons living with HIV (PLWH). We conducted automated searches of electronic databases (i.e., MEDLINE, EMBASE, PsycINFO, CINAHL) and manual searches of journals, reference lists, and listservs. Interventions were eligible for the review if they were U.S.-based, published between 1996 and 2011, intended to improve HIV medication adherence behaviors of PLWH, evaluated the intervention using a comparison group, and reported outcome data on adherence behaviors or HIV viral load. Each intervention was evaluated on the quality of study design, implementation, analysis, and strength of findings. Of the 65 eligible interventions, 10 are EBIs. The remaining 55 interventions failed to meet the efficacy criteria primarily due to null findings, small sample sizes, or low retention rates. Research gaps and future directions for development of adherence EBIs are discussed.
Introduction
Due to the availability and advancement of highly active antiretroviral therapy (HAART) as well as an increasing number of persons living with HIV (PLWH), there has been an increased focus on both health promotion and HIV prevention for PLWH [1] . The individual health benefits of antiretroviral treatment (ART) for PLWH are clear [2] [3] [4] [5] [6] ; however, the success of ART is related to the patient's level of medication adherence. High adherence rates have consistently been associated with decreased viral load, less risk of progression to AIDS, and a decreased risk of developing drug-resistant strains of HIV [7] [8] [9] [10] , whereas poor adherence is associated with treatment failure, lower CD4 cell counts, and increased mortality [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Recently, the HIV Prevention Trials Network 052 study comparing early versus delayed ART for HIV patients with CD4 cell counts between 350 and 550 cells/mm 3 found a 96 % reduction in the number of linked HIV transmissions for those with early ART initiation. This finding suggests that, in addition to individual health benefits, ART has significant prevention benefits in that successful viral suppression can lead to a reduction in HIV transmission risk [20] .
However, the most recent surveillance data from the Centers for Disease Control and Prevention (CDC) showed that among 1.15 million PLWH in the United States (U.S.) in 2009, 33 % were prescribed ART and only 25 % were estimated to have the suppressed viral load needed to maximally prolong health and prevent transmission [21] .
Optimal adherence to ART is critical to fully achieve both the clinical and preventive benefits of ART. However, a recent meta-analysis suggests that adherence levels remain suboptimal. In 84 studies across 20 countries, an average of 62 % of participants reported C90 % adherence to HAART [22] . Maintaining high levels of adherence to medications for a chronic condition is extremely difficult and often requires additional support. Some barriers to HIV medication adherence are identified, including lack of knowledge and competence regarding how to maintain good adherence [11, [23] [24] [25] [26] ; patient-provider relationship [8, 11, 27, 28] ; and psychosocial factors such as depression, anxiety, fatigue, and stress, as well as lack of social support and negative attitudes about the HIV disease [8, 11, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
The scientific literature focusing on developing and testing behavioral interventions to address identified barriers and help PLWH adhere to their medications continues to expand, particularly as PLWH are living longer and as medication regimens are evolving over time. Overall, the positive effects of these interventions on adherence behaviors and viral load has been highlighted through several quantitative and qualitative systematic reviews [25, [33] [34] [35] [36] [37] [38] . These reviews are useful for understanding the overall potential for interventions to improve medication adherence; however, they typically do not critically evaluate the study design, implementation, analysis, and strength of findings of individual interventions. Doing so may help identify model programs, with rigorous methods and strong findings, which could be used by prevention providers within their own clinics or communities. Therefore, there remains a need to supplement these reviews by identifying individual interventions with evidence of efficacy.
CDC's HIV/AIDS Prevention Research Synthesis (PRS) Project
In order to identify evidence-based interventions (EBIs) for the HIV prevention field, the CDC established the HIV/ AIDS PRS project in 1996 (http://www.cdc.gov/hiv/topics/ research/prs/index.htm) [39] . The aim of the PRS project is to review and synthesize the cumulative body of evidence of HIV prevention interventions from the scientific research literature to help inform policy decisions and programmatic efforts within the U.S. and to guide future research. Since 1996, the PRS team has been conducting meta-analyses and systematic efficacy reviews focused on interventions to change sex and drug behaviors related to HIV acquisition and transmission. In late 2008, the PRS team expanded the scope to include medication adherence interventions and began a new systematic review to identify EBIs for improving HIV medication adherence among PLWH (referred to as ''adherence EBIs'').
This article focuses on the findings from the PRS systematic efficacy review process for identifying adherence EBIs. First, we briefly describe methods for developing the efficacy criteria and the final criteria for evaluating adherence interventions. Second, we provide a summary of the adherence EBIs identified through our systematic review process and compare the EBIs to interventions that did not meet our efficacy review criteria. Finally, we provide recommendations for future programmatic and research activities.
Methods

PRS Efficacy Criteria for HIV Medication Adherence Interventions
Between 2008 and 2010, the PRS team conducted a series of activities to develop the efficacy criteria to evaluate the evidence from published HIV medication adherence intervention studies. These included repeated consultations with CDC scientists, key federal partners including the National Institute of Mental Health (NIMH), the National Institute of Drug Abuse (NIDA), and the Health Resources and Services Administration (HRSA), and non-federal researchers with substantial expertise in HIV medication adherence issues.
The existing PRS efficacy criteria for HIV-related sex and drug risk reduction interventions were used as the initial framework and were adapted to address issues relevant for adherence intervention studies.
To ensure a reasonable level of confidence that observed changes could be attributed to the intervention under evaluation, these criteria focus heavily on elements related to internal validity and assess risk of bias in individual studies (e.g., potential bias resulted from allocation method, reassignment, baseline group equivalence, attrition, measurement and confounding factors). The criteria assess factors across four domains: the quality of study design, quality of study implementation, quality of study analysis, and strength of evidence. Based on the overall set of criteria, adherence EBIs are classified as either goodevidence or best-evidence. Good-evidence interventions are considered to have been evaluated using scientifically sound methods and provide sufficient evidence of efficacy and must meet each element in the efficacy criteria (Table 1) . Best-evidence interventions are considered to have been rigorously evaluated and provide the strongest evidence of efficacy and must meet additional elements within the efficacy criteria (Table 2 ). In Tables 1 and 2 , we list the PRS efficacy criteria and indicate whether the criteria were supported by other systematic review or evidence-based groups, based on empirical evidence, or recommended by our consultants. Appendix A in supplementary material provides more detailed explanation on the complex elements of our efficacy criteria.
Systematic Search Strategy
Two librarians with expertise in systematic searches developed and conducted a comprehensive and systematic search strategy, including both annual automated and quarterly manual searches, to identify all relevant HIV medication adherence intervention reports for the PRS cumulative database. The annual automated search component focused on literature published between 1996 and 2011 using the following electronic databases and platforms: CINAHL (EBSCOhost platform), EMBASE (OVID), MEDLINE (OVID), and PsycINFO (OVID). We selected 1996 as the start date for our search to be consistent with the year that HAART was made more available to HIV positive persons in the U.S. The automated search component used indexing and keyword terms, cross-referenced using Boolean logic, in four areas: (a) HIV/AIDS; (b) intervention and prevention evaluation; (c) HAART, anti-retroviral therapy or treatment; and (d) adherence. Indexing terms for the electronic searches were varied according to each database, but keywords remained constant across all databases and searches. The search was not restricted by country or language. The last automated search for this efficacy review was conducted in March 2012. As required by the PRISMA checklist, the full search strategy of the MEDLINE database is provided in Appendix B in supplementary material. The searches of the other databases are available from the corresponding author.
The quarterly manual search component involved reviewing all articles published in the previous 3 months of 20 journals to identify potentially relevant articles not yet indexed in electronic databases (see Appendix C in supplementary material). The last quarterly manual search for this review was conducted in January 2012. To supplement our routine automated and manual searches, PRS also examined the reference lists of relevant published articles, HIV/AIDS Internet listserves (e.g., www.RobertMalow. org), various research databases (i.e., ISI Web of Knowledge, RePORTER, Cochrane), and unpublished manuscripts submitted by study authors. Further details of the supplemental searches can be obtained from the corresponding author.
Study Selection
We searched the CDC's PRS database for eligible studies. Studies were included for the efficacy review if they (1) were conducted in the U.S. or a U.S. territory; (2) were published or accepted for publication between 1996 and 2011; (3) reported on an intervention that focused on improving HIV medication adherence among PLWH by including either an educational or behavioral component (i.e., excluding studies exclusively comparing drug regimens), treatment delivery method (e.g., directly administered antiretroviral therapy [DAART]), or monitoring device to facilitate adherence (e.g., pager); (4) compared an intervention group to a comparison group; and (5) reported data on at least one behavioral adherence outcome (i.e., as measured by medication event monitoring system [MEMS caps], electronic data monitoring [EDM] , pill count, selfreport, or pharmacy refill) or laboratory-based HIV viral load outcome (i.e., not self-report). Our review allowed for behavioral interventions delivered to individuals, small groups or communities, but excluded interventions that were exclusively changes in policy or structure. Linked citations, defined as publications providing additional information on the same study, were included in this efficacy review if they provided relevant intervention evaluation information.
Qualitative Data Coding
Pairs of trained coders independently evaluated each eligible intervention against the newly established efficacy criteria on study design, implementation, analysis, and strength of findings. The reliability between coders on the 
Additional limitations to evaluate
The totality of the limitations (as described below) cannot introduce considerable bias that substantially reduces the confidence placed on the findings efficacy coding was not calculated. All the coders go through standardized and stringent coding training and, on average, the overall percentage agreement among the trained coders is 96 % with a kappa rate of 80 % on our regular citation-level coding, indicating a high inter-rater reliability. All discrepancies were reconciled between paired coders. The first author of individual studies was contacted to provide missing data or clarification as needed. Of the 15 authors (out of 57 studies) we contacted for additional information, the response rate was 87 %. Final efficacy determination for each study was reached by PRS group consensus.
Results PRS evaluated 65 interventions from the 57 unique studies eligible for this efficacy review (Fig. 1 ). Of these, we identified 10 interventions from 9 unique studies that met the good-evidence efficacy criteria and are considered evidence-based [40] [41] [42] [43] [44] [45] [46] [47] [48] . Fifteen percent of eligible medication adherence interventions (i.e., 10/65) met the PRS efficacy criteria. Below, we describe the characteristics of the 10 EBIs.
Population Characteristics of EBIs
All of the EBIs targeted adults. As shown in Table 3 , eight interventions targeted clinic patients [40-43, 45, 47, 48] and two targeted drug users [40, 44] . None of the EBIs specifically targeted men who have sex with men (MSM), although one targeting discordant couples included gay male couples [46] and one included a majority of MSM participants [45] . One intervention targeted treatment-naïve individuals initiating therapy [43] , four targeted treatmentexperienced individuals [41, 45, 46, 48] , and five included both treatment-experienced and -naïve individuals [40, 42, 44, 47] . All 10 EBIs had greater than 50 % minority participants (range 53-94 %), six of which included a majority of African Americans [40] [41] [42] [43] [44] 46] . In addition, all 10 interventions had greater than 50 % male participants (range 52-88 %), and participants ranged in age from 19 to 67 years.
Intervention Characteristics of EBIs
Overall, there were three discrete interventions, defined as those in which participants had to receive all intervention [53] , and Social Action Theory [54] . As shown in Table 4 , six EBIs were delivered in public or private outpatient clinics (one of which was also implemented in community-based organizations [41, 42] ). Additional intervention settings included a mobile community health care van [40] , anywhere the patient had access to a pager [47] , and residential and community settings [48] . The interventions were delivered by a health care provider such as a nurse (n = 5), peer (n = 3), community/outreach worker (n = 2), or facilitator (n = 3). All EBIs included components delivered to individuals, except SMART Couples [46] which was group-based. Three interventions included both individual and group components: Project HEART [43] , the Integrated HIV Risk Reduction and Adherence Intervention [42] , and Peer Support [47] . Although the content of the EBIs differed substantially, the majority of the interventions included a cognitive-behavioral component (e.g., addressing barriers to adherence and problem-solving). Three interventions focused on skill-building: technical (e.g., practice medication adherence with candies), personal (e.g., practice ways to overcome barriers), and interpersonal (e.g., couple communication exercises). In addition to medication adherence, one EBI focused on patientprovider relationships in clinic settings [45] , and three focused on both medication adherence and safer sex [41, 42, 46] . Social support was also incorporated as an important component in three EBIs [43, 46, 47] .
Outcomes Measures of EBIs
Among the ten EBIs, one measured viral load only [44] , two measured adherence behavior only [41, 42] , and the remaining seven measured both viral load and adherence behavior. Among the nine interventions that measured adherence behavior, three relied on MEMS caps only [43, 46, 48] , two relied on EDM data and self-report ( [47] Peer Support and Pager Messaging), one relied on unannounced pill counts and pharmacy prescription records [42] and three relied on self-report only [40, 41, 45] .
Among the seven EBIs that assessed viral load and adherence behavior, three observed a significant intervention effect on viral load only and three on adherence behavior only. Only one found a significant intervention effect on both outcomes [45] . Significant intervention effects were observed over a range of follow-up times, from 3 to 18 months post-initiation of the seven interventions with repetitive-dosing components and 1-13 months postcompletion of the three discrete interventions [41, 42, 46] .
Reasons for Not Meeting Best-Evidence Criteria
The ten good-evidence interventions did not meet the bestevidence efficacy criteria for the following reasons (not mutually exclusive): did not find a significant positive intervention effect on both behavioral and biologic measures of adherence (n = 9; three of these did not measure both outcomes); did not meet the requirement for retention (n = 2) or follow-up time point (n = 3), did not impute missing data (n = 4) or adjust for clusters (n = 2). One additional study was identified as a non-RCT with moderate allocation bias. Most of these limitations are a result of the design of the study and/or analysis of data.
Comparison Between EBIs and Non-EBIs
Although 10 interventions were identified as EBIs, 55 interventions from 48 unique studies did not meet the minimal criteria for good-evidence. The most common reasons (not mutually exclusive) were: small sample size (n = 31; 56 %), null/non-significant findings (n = 18; 33 %), no appropriate follow-up (n = 12; 22 %), poor retention (n = 7; 13 %). Several studies had other design or analytic issues that did not meet criteria (n = 9; 22 %; e.g., biased allocation to study arms, harmful negative effects, substantial missing data). The comparisons between the 10 EBIs and the 55 non-EBIs on key population and intervention characteristics are shown in Table 5 . Both groups are similar on several population and intervention characteristics; however, there are a couple notable differences. All of the EBIs had at least one positive significant outcome (100 %) whereas only two-third (64 %) of the non-EBIs did. More EBIs than non-EBIs targeted both treatmentexperienced and -naïve patients combined (50 vs. 7 %). Additionally, more non-EBIs than EBIs focused on specific populations (e.g., women only, men only, high risk youth only); whereas, more EBIs include a majority of African American participants than non-EBIs (60 vs. 49 %).
Discussion
Given the importance of adherence for both prevention and treatment efficacy, it is very encouraging to have identified 10 EBIs for promoting adherence among PLWH. These interventions can serve as model programs for providers and other prevention planners looking to implement EBIs best suited for their community's needs. The 10 EBIs represent 15 % of eligible interventions (i.e., 10/65) for this first efficacy review of HIV medication adherence interventions. In comparison, the first published PRS sex and drug risk reduction efficacy review, which included a review of the scientific literature, published from 2000 to 2004, identified 18 % of eligible interventions as meeting the original PRS efficacy criteria [103] . Over the years, the scientific field has evolved, with advancements in research and improvements in study quality. Cumulatively, through 2011, roughly 20-22 % of the eligible risk reduction behavioral interventions have The 55 interventions that did not meet the efficacy criteria reported similar population and intervention characteristics but failed to meet evidence-based criteria, primarily due to small sample sizes, null findings or low retention rates. Among these 55 interventions, 35 (64 %) found at least 1 significant positive intervention effect. These interventions could be considered for re-testing, in particular with more rigorous evaluation methods.
Although the study samples across the 10 EBIs consist of greater than 50 % minority participants, we do not know specifically the percentage of MSM of color or minority women across these studies. Non-EBIs more often targeted specific populations (e.g., women, high-risk youth, MSM, men) whereas the EBIs more often targeted general clinic populations. Given that the EBIs tended to target the general HIV clinic population, this suggests that these effects may be robust and can be generalized to a wide variety of HIV care clinics. One exception may be HIVpositive injection drug users (IDUs) since their lifestyle and active substance use may create a barrier to adherence that others may not experience. The two EBIs targeting drug users were DAART interventions, which may not be easily implementable or sustainable in typical HIV clinics. Systematic reviews of DAART interventions have shown them to be efficacious during implementation but not so after DAART services end. Future research should evaluate the extent to which current and newly developed interventions are effective for IDUs, drug users, and other groups with unique structural barriers (such as homeless persons) to adherence.
Those involved in developing and implementing HIV medication adherence interventions also have the opportunity to engage PLWH at the onset of treatment and to help them establish a high level of adherence from the beginning. Of the ten EBIs, only one focuses exclusively on treatment-naïve participants [43] . There is opportunity here for providers to identify participants as soon as they are linked to care and assist them in developing and maintaining good adherence behaviors.
A few limitations of this review and the literature warrant comment. First, our criteria primarily focused on internal validity and did not focus on evidence from replication studies, external validity, scalability, cost and population-level impact which should be incorporated in the criteria as the medication adherence field advances. Second, our criteria are designed to evaluate risk of bias in individual studies; however, there is a potential risk of bias across studies in our review as we only evaluated published reports. Third, there remains considerable variability regarding a ''gold standard'' for adherence measurement in research and practice. As recently recommended by Williams and her colleagues, the prevention field is encouraged to adopt quality standards for measuring and reporting on adherence measures so that adherence behaviors are reported consistently and reliably [104] . Despite these limitations, there are a few implications from our review findings for further research. For improving the quality of study design, implementation, and analyses, researchers should aim to assess both behavioral and biologic measures of adherence, develop strategies to retain participants over longer periods of time (particularly among prioritized populations and those known to have poor retention in care), and use robust analytic methods for dealing with complex data that result from missing data and design elements (e.g., allocating clusters of individuals). We also encourage researchers to use the PRS efficacy criteria to evaluate their own interventions as they are being developed. The current fiscal environment requires a deliberate effort to identify and support the interventions most likely to have a large impact on the HIV epidemic. It is imperative that EBIs are also evaluated to determine which ones are most easily scalable and cost-effective. Researchers, therefore, are further encouraged to report cost data related to intervention implementation.
Translating EBIs into Practice
Similar to recommendations in other public health sectors, [105, 106] the National HIV/AIDS Strategy [1] calls for greater focus on evidence-based HIV prevention by drawing upon interventions and strategies with proven efficacy. Thus, once EBIs are identified, they need to be made available and accessible for wide-scale use in practice to achieve a larger public health impact. Many of the HIV risk reduction interventions previously identified by PRS as EBIs (http://www. cdc.gov/hiv/prevention/research/compendium/index.html) have been translated into easy-to-use intervention materials and are being disseminated to prevention providers across the nation (https://www.effectiveinterventions.org) [107] . Recently, CDC has developed web-based and e-learning training and implementation materials for five of these medication adherence EBIs for national dissemination and widespread practice (https://www.effectiveinterventions.org) [107] . These interventions were designed for healthcare and/or non-healthcare providers. For clinic settings, there is a need for brief intervention tools that are feasible to be implemented within the short period of time that providers have with their patients during routine HIV care. The more intensive EBIs can be more realistically implemented in non-healthcare settings to provide additional support to improve PLWH's ART adherence behavior. Efforts in both healthcare and non-healthcare settings are important to fully support PLWH in achieving optimal adherence to ART and viral load suppression.
Conclusions
This efficacy review contributes to the research translation of HIV medication adherence interventions; that is, translating proven scientific research into routine practice. Our systematic review identified several EBIs that can serve as model programs for providers and other prevention planners who are looking to implement evidence-based HIV medication adherence interventions best suited for their community's needs. The medication adherence field can be further improved if identified research opportunities are explored. Scalable, cost-effective, evidence-based adherence interventions are imperative for improving the health outcomes and reducing HIV transmission risk among PLWH.
